TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16850006

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 40
Study: 16128679

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg intravenously
Number of subjects: 20
Study: 11230282

Group type: EXPERIMENTAL
Intervention: Vitamin C repletion with 117 mg/d for 1 month after 1 month of depletion
Number of subjects: 68
Study: 9035281

Group type: EXPERIMENTAL
Intervention: Hypertonic 7.5% NaCl + 6% dextran (HSD, n = 101)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Isotonic 0.9% NaCl solutions (IS, n = 111)
Number of subjects: 212
Study: 8197242

Group type: EXPERIMENTAL
Intervention: Toe spreader on
Number of subjects: 18

Group type: COMPARATOR
Intervention: Toe spreader off
Number of subjects: 18
Study: 3297375

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam combined with high-dose metoclopramide (3 mg/kg) infused twice 3 h apart with i.v. dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sublingual lorazepam combined with high-dose metoclopramide (3 mg/kg) infused twice 3 h apart without i.v. dexamethasone
Number of subjects: 60
Study: 31680180

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) administered on Day 0-3
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) administered on Day 4-7
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence imaging (ICG FI)
Number of subjects: 32
Study: 29127786

Group type: EXPERIMENTAL
Intervention: ASCOS (Adolescent Smoking Curiosity Scale)
Number of subjects: 101
Study: 27571099

Group type: EXPERIMENTAL
Intervention: Oat bran (4.5, 13.6 or 27.3 g) mixed in water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oat β‐glucan
Number of subjects: 10
Study: 24014477

Group type: EXPERIMENTAL
Intervention: Systemic group therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Analytic group therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 106
Study: 21910945

Group type: EXPERIMENTAL
Intervention: Combination of broccoli sprouts and GRP powder
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts alone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GRP powder alone
Number of subjects: 4

Group type: COMPARATOR
Intervention: GRP powder meal
Number of subjects: 4

Group type: COMPARATOR
Intervention: Broccoli sprout meal
Number of subjects: 4
Study: 20861150

Group type: EXPERIMENTAL
Intervention: Wuhan Smoking Prevention Program
Number of subjects: 1391

Group type: COMPARATOR
Intervention: 30-day smokers
Number of subjects: 1391
Study: 17929073

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1240
Study: 15962567

Group type: EXPERIMENTAL
Intervention: Agricultural population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-specific fertility rate (fx)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age group 25-29 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with national fertility
Number of subjects: 0
Study: 14663654

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 0
Study: 11380294

Group type: EXPERIMENTAL
Intervention: EPO (NeoRecormon) and oral iron for 4 weeks prior to surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral iron only for 4 weeks prior to surgery
Number of subjects: 31
Study: 9409274

Group type: EXPERIMENTAL
Intervention: High-fat meals (70 g of either rapeseed oil, olive oil, sunflower oil, palm oil, or butter)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-fat meals (6% of energy from fat)
Number of subjects: 18
Study: 8298714

Group type: EXPERIMENTAL
Intervention: Sandoglobulin (SG) 0.5 g/kg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pentaglobin (PG) 5 ml/kg/day
Number of subjects: 34
Study: 3681277

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg (H-2 receptor antagonist)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg (H-1 receptor antagonist)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined antihistamines (Diphenhydramine 50 mg and Cimetidine 300 mg)
Number of subjects: 17
Study: 31647775

Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (t‐PBM) with near‐infrared light (NIR), self-administered daily for 20 minutes, 830 nm peak wavelength, average irradiance 30 mW/cm2, average fluence 36 J/cm2, total energy delivered per session 2.9 kJ.
Number of subjects: 15
Study: 28894551

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Mometasone
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 25869405

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: High fraction‐inspired oxygen facial mask (HFFM)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 124

Group type: COMPARATOR
Intervention: HFFM
Number of subjects: 124
Study: 23931128

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BioPure MTAD
Number of subjects: 5

Group type: COMPARATOR
Intervention: 5.25% NaOCl (Control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (1.8 W, 120 mJ, 15 Hz)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W, 100 mJ, 15 Hz)
Number of subjects: 5
Study: 21896838

Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg
Number of subjects: 260

Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 260
Study: 19691092

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 244

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 244
Study: 18007136

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux or danaparoid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term low-molecular-weight heparins therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium vitamin D supplementation during pregnancy
Number of subjects: 0
Study: 15136618

Group type: EXPERIMENTAL
Intervention: Salvage index < 0.5
Number of subjects: 765

Group type: COMPARATOR
Intervention: Salvage index >= 0.5
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Myocardial salvage index
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Initial perfusion defect
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 765
Study: 11297307

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Inactively treated patients
Number of subjects: 116
Study: 9678815

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m., amoxycillin 500 mg q.d.s. and secnidazole 2 g on alternate days for 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m., clarithromycin 500 mg b.d. and secnidazole 2 g on alternate days for 1 week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m., pefloxacin 400 mg o.m. and secnidazole 2 g on alternate days for 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall ulcer healing rate
Number of subjects: 60
Study: 8305389

Group type: EXPERIMENTAL
Intervention: Intervention debulking surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 79
Study: 2498449

Group type: EXPERIMENTAL
Intervention: CO2MV
Number of subjects: 42

Group type: COMPARATOR
Intervention: IMV
Number of subjects: 42

Group type: COMPARATOR
Intervention: TTM
Number of subjects: 42
Study: 31898517

Group type: COMPARATOR
Intervention: Patient advice and an insole
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Patient advice, an insole, and self-dosed heavy-slow resistance training (heel raises)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Patient advice, an insole, heavy-slow resistance training, and an ultrasound-guided corticosteroid injection
Number of subjects: 180
Study: 31205144

Group type: EXPERIMENTAL
Intervention: 11C-methionine PET/CT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 11C-choline PET/CT
Number of subjects: 19
Study: 28437667

Group type: EXPERIMENTAL
Intervention: Ingroup perception (high entitativity, low group value)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ingroup perception (low entitativity)
Number of subjects: 60
Study: 25201055

Group type: EXPERIMENTAL
Intervention: Specialist health service use
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Parental mental health problems
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Stimulant medication prescription
Number of subjects: 162
Study: 24358625

Group type: EXPERIMENTAL
Intervention: In-office balloon dilation of maxillary sinus ostia and ethmoid infundibula
Number of subjects: 74
Study: 21685533

Group type: EXPERIMENTAL
Intervention: Abacavir + Lamivudine (ABC+3TC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tenofovir + Emtricitabine (TDF+FTC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 19622125

Group type: EXPERIMENTAL
Intervention: Apligraf (n=17)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional management (n=4)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thiersch (n=1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HR‐US monitoring
Number of subjects: 20
Study: 17121312

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/copolymer dentifrice
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 140
Study: 15271870

Group type: EXPERIMENTAL
Intervention: Lipiodol flushing
Number of subjects: 158

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 158
Study: 11407953

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 109
Study: 9136492

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (DEX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8566261

Group type: EXPERIMENTAL
Intervention: 50 micrograms transdermal E2 plus 5 mg medroxyprogesterone acetate (MPA) continuously
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogen plus 2.5 mg MPA continuously
Number of subjects: 2
Study: 2107241

Group type: EXPERIMENTAL
Intervention: Pollinex-R hyposensitization injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Budesonide aqueous nasal steroid spray, 400 micrograms daily
Number of subjects: 60
Study: 394282

Group type: EXPERIMENTAL
Intervention: Diclofenac (Voltarol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ibuprofen (Brufen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both Diclofenac and Ibuprofen
Number of subjects: 60
Study: 31772078

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) using Walkaide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual gait rehabilitation
Number of subjects: 200
Study: 28221862

Group type: EXPERIMENTAL
Intervention: Clofarabine-based combination (CLARA)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional high-dose cytarabine (HDAC)
Number of subjects: 221
Study: 25888469

Group type: EXPERIMENTAL
Intervention: PFIT‐s
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FSS‐ICU
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IMS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: SPPB
Number of subjects: 66
Study: 24440809

Group type: EXPERIMENTAL
Intervention: Ondansetron + ST36 acupuncture point injection (group C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ondansetron (group O)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Acupuncture point injection (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 160
Study: 22686081

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) + routine therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 68
Study: 21311490

Group type: EXPERIMENTAL
Intervention: Akatinol memantine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 41
Study: 17761829

Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib <600 mg/day
Number of subjects: 0
Study: 16212141

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 11846188

Group type: EXPERIMENTAL
Intervention: Supplemental continuous oxygen therapy (2 L x min(‐1) via nasal prongs; n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No oxygen (n = 19)
Number of subjects: 38
Study: 10372934

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day + clarithromycin 250 mg twice daily (group I, n = 22)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day + clarithromycin 250 mg twice daily + amoxycillin 500 mg three times daily (group II, n = 20)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate 120 mg four times daily + amoxycillin 500 mg three times daily + metronidazole 400 mg three times daily (group III, n = 22)
Number of subjects: 64
Study: 8839658

Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tropisetron 5 mg by slow i.v.i.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tropisetron by slow i.v.i., followed by 10 mg metoclopramide i.v.
Number of subjects: 10
Study: 1733530

Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitor (Fastrac)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: End-tidal CO2 measurement (PETCO2)
Number of subjects: 22
Study: 6437892

Group type: EXPERIMENTAL
Intervention: trimipramine 50 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 30342064

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 28013381

Group type: EXPERIMENTAL
Intervention: 4000 IU cholecalciferol
Number of subjects: 34

Group type: COMPARATOR
Intervention: 400 IU cholecalciferol
Number of subjects: 34
Study: 26256137

Group type: EXPERIMENTAL
Intervention: Topical Matricaria chamomilla (Chamomile) oil, applied 3 times/day for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac, applied 3 times/day for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, applied 3 times/day for 3 weeks
Number of subjects: 0
Study: 23708173

Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 2982

Group type: COMPARATOR
Intervention: Primary Stenting
Number of subjects: 2982
Study: 21490035

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation (MR) patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation (MR) patients with recurrence
Number of subjects: 190
Study: 19713691

Group type: EXPERIMENTAL
Intervention: Supervised stretching program (12 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no physical activity)
Number of subjects: 20
Study: 17267835

Group type: EXPERIMENTAL
Intervention: Bilateral salpingo‐oophorectomy (BSO)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ovarian conservation
Number of subjects: 161
Study: 15505446

Group type: EXPERIMENTAL
Intervention: Propofol infusion at rates of 0.1, 0.3, 0.5, 0.7, or 0.9 microg . ml . min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Automated Responsiveness Monitor (ARM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 18
Study: 11273219

Group type: EXPERIMENTAL
Intervention: Vaginal lavage with 0.2% chlorhexidine
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Vaginal lavage with 0.4% chlorhexidine
Number of subjects: 606

Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 606
Study: 8263316

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 4030699

Group type: EXPERIMENTAL
Intervention: social skills training plus placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: short‐term psychotherapy plus placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: amitriptyline alone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: social skills training plus amitriptyline
Number of subjects: 125
Study: 31533605

Group type: EXPERIMENTAL
Intervention: HIRT + Ursolic Acid (UA) supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: HIRT + Placebo
Number of subjects: 22
Study: 29659201

Group type: EXPERIMENTAL
Intervention: Eluxadoline 1000 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29071928

Group type: COMPARATOR
Intervention: CANT-0 g group (no Cantharides)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CANT-1.5 g group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CANT-3.0 g group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CANT-1.5 g and CANT-3.0 g groups
Number of subjects: 120
Study: 24985376

Group type: EXPERIMENTAL
Intervention: Self-efficacy theory health education
Number of subjects: 260
Study: 23265344

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (1 g/day)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 21211295

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1000 mg 3 times per day for 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.15% ganciclovir ophthalmic gel, 4 times per day, and 0.1% fluorometholone eye drops, 3 times per day (test group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (same ophthalmic gel and eye drops without oral ganciclovir)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 60
Study: 18802881

Group type: EXPERIMENTAL
Intervention: LigaSure electrocautery with hepatic inflow occlusion
Number of subjects: 159

Group type: COMPARATOR
Intervention: Clamp‐crushing technique alone with hepatic inflow occlusion
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: LigaSure electrocautery
Number of subjects: 159

Group type: COMPARATOR
Intervention: Clamp‐crushing technique alone
Number of subjects: 159
Study: 16642901

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + beta tricalcium phosphate (3-TCP) and a collagen membrane
Number of subjects: 7

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 7
Study: 14671522

Group type: EXPERIMENTAL
Intervention: New experimental device (low-profile, fixed-angle plate)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Association for the Study of Internal Fixation (ASIF) T‐plate
Number of subjects: 2
Study: 10803938

Group type: EXPERIMENTAL
Intervention: Meropenem (1g/8 h)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Ceftazidime (2 g/8 h)
Number of subjects: 101
Study: 8628614

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg/4 mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nebulized adrenaline (4 mg/4 mL)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study: 1320305

Group type: EXPERIMENTAL
Intervention: Anticholest (apple-pectin-guar soft-drink) at 1 cup (17 g) every second day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anticholest (apple-pectin-guar soft-drink) at 1 cup a day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anticholest (apple-pectin-guar soft-drink) at 2 cups a day
Number of subjects: 33
Study: 3535565

Group type: EXPERIMENTAL
Intervention: Meptazinol 3 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 31699003

Group type: COMPARATOR
Intervention: Moderate altitude resistance training (H; 2320 m asl)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Normoxic resistance training (N; <700 m asl)
Number of subjects: 13
Study: 29492908

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with D2 lymphadenectomy for advanced gastric cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentinel node navigation surgery and related fluorescence molecular imaging techniques
Number of subjects: 0
Study: 27040723

Group type: EXPERIMENTAL
Intervention: CABG plus medical therapy
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1212
Study: 24831116

Group type: EXPERIMENTAL
Intervention: Skechers Shape‐Ups
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reebok Easy Tone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard shoe
Number of subjects: 16

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 16
Study: 22577468

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 303
Study: 21594900

Group type: EXPERIMENTAL
Intervention: Targeted preventive intervention integrated within acute medical care
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study: 19695435

Group type: EXPERIMENTAL
Intervention: Topotecan with radiation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Radiation alone (Control)
Number of subjects: 140
Study: 16468292

Group type: EXPERIMENTAL
Intervention: LP PDL-mediated ALA PDT (14 patients)
Number of subjects: 19

Group type: COMPARATOR
Intervention: LP PDL-only control (2 patients)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral antibiotics, oral contraceptives, and topicals control (2 patients)
Number of subjects: 19